文献速递泌尿系结石

定制代谢检查能否减少泌尿系结石复发?一篇叙述性综述

Does bespoke metabolic investigation reduce urinary stone recurrence? A narrative review
RSS 订阅 · BJU International · 2026-10-21

该叙述性综述检索了PubMed/MEDLINE、Cochrane图书馆和Europe PMC(1980年1月至2026年3月)的随机试验、对照队列和系统综述,并结合EAU、AUA、NICE和ACP指南,评估个体化代谢检查及靶向饮食和药物治疗能否减少结石复发。结果显示,纠正明确尿液异常的干预措施均能减少复发,在高危、复发和术后患者中定制预防证据最强。

要点

  • 纠正明确尿液异常的干预可减少结石复发,增加液体摄入约减半复发风险。
  • 靶向药物可进一步降低复发,但NOSTONE试验未发现噻嗪类显著获益。
  • 定制预防在复发、高危和术后结石患者中证据最强。

核心结论

  • 定制预防在复发、高危和术后结石患者中证据最强。
  • 识别异常、纠正异常、确保依从并通过重复检测确认反应,最有机会减少结石复发和残余结石生长、改善健康相关生活质量并降低费用。

研究设计与样本

  • 叙述性综述,检索PubMed/MEDLINE、Cochrane图书馆和Europe PMC(1980年1月至2026年3月)的随机试验、对照队列和系统综述。
  • 补充检索EAU、AUA、NICE和ACP指南及参考文献手工检索,对象为成人代谢评估与结石复发预防。

主要发现

  • 增加液体摄入约使结石复发减半(相对风险[RR] 0.45–0.55)。
  • 正常钙、减少钠、减少动物蛋白饮食在高钙尿性草酸钙结石形成者中达到类似减少(RR 0.49)。
  • 靶向药物治疗进一步降低复发:枸橼酸钾RR约0.25,噻嗪类0.52,别嘌醇0.59。
  • 严格的NOSTONE试验(ClinicalTrials.gov标识符:NCT03057431)未发现噻嗪类显著获益。
  • 冲击波碎石和经皮肾镜取石术后,药物治疗减少结石形成和残余碎片再生。

关键数值与推荐

  • 24小时尿液导向治疗优于经验性治疗的证据仅限于高危患者,选择性治疗显著减少结石相关事件。
  • 结石病损害疾病特异性生活质量且费用高昂,因此预防结石复发可节省费用。

临床怎么用

  • 对复发、高危和术后结石患者应优先考虑定制代谢评估和靶向预防。
  • 识别并纠正明确尿液异常,确保治疗依从性,并通过重复检测确认反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To examine whether individualised (‘bespoke’) metabolic investigation and targeted dietary and medical therapy reduces urinary stone recurrence, and whether the approach also improves health-related quality of life (HRQOL) and lowers financial and environmental cost. Methods In this narrative review we searched PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), the Cochrane Library and Europe PubMed Central (PMC) (January 1980 to March 2026) for randomised trials, controlled cohorts and systematic reviews on metabolic assessment and stone recurrence prevention in adults, supplemented by European Association of Urology (EAU), American Urological Association (AUA), National Institute for Health and Care Excellence (NICE) and American College of Physicians (ACP) guidance and by hand-searching of reference lists. Results Interventions that correct a defined urinary abnormality each reduce stone recurrence. Increased fluid intake approximately halves it (relative risk [RR] 0.45–0.55); a normal calcium, reduced sodium, reduced animal protein diet achieves a similar reduction in hypercalciuric calcium-oxalate formers (RR 0.49); and targeted pharmacotherapy lowers it further (potassium citrate RR approximately 0.25, thiazides 0.52, allopurinol 0.59), although the rigorous NOSTONE trial (ClinicalTrials.gov identifier: NCT03057431) found no significant thiazide benefit. After shockwave lithotripsy and percutaneous nephrolithotomy, medical therapy reduces stone formation and residual-fragment regrowth. Evidence that 24-h-urine-directed therapy outperforms empirical therapy is confined to high-risk patients, in whom selective treatment yields significantly fewer stone-related events. Stone disease impairs disease-specific quality of life and is costly, so preventing stone recurrence is cost-saving. Conclusions The case for bespoke prevention is strongest in recurrent, high-risk and post-procedural stone formers. Identifying the abnormality, correcting it, ensuring adherence and confirming the response by repeat testing offers the best chance to reduce stone recurrence and residual-stone growth, improve HRQOL, and lower financial cost.

来源:BJU International,查看原文。版权归原作者所有。

引用

  1. BJU International:Does bespoke metabolic investigation reduce urinary stone recurrence? A narrative review

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。